CN100439394C - 分泌性细菌效应蛋白的药物用途 - Google Patents

分泌性细菌效应蛋白的药物用途 Download PDF

Info

Publication number
CN100439394C
CN100439394C CNB028105052A CN02810505A CN100439394C CN 100439394 C CN100439394 C CN 100439394C CN B028105052 A CNB028105052 A CN B028105052A CN 02810505 A CN02810505 A CN 02810505A CN 100439394 C CN100439394 C CN 100439394C
Authority
CN
China
Prior art keywords
leu
ser
asn
ile
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028105052A
Other languages
English (en)
Chinese (zh)
Other versions
CN1531549A (zh
Inventor
J·M·萨顿
C·C·肖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of CN1531549A publication Critical patent/CN1531549A/zh
Application granted granted Critical
Publication of CN100439394C publication Critical patent/CN100439394C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB028105052A 2001-05-24 2002-05-21 分泌性细菌效应蛋白的药物用途 Expired - Fee Related CN100439394C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
GB0112687.9 2001-05-24

Publications (2)

Publication Number Publication Date
CN1531549A CN1531549A (zh) 2004-09-22
CN100439394C true CN100439394C (zh) 2008-12-03

Family

ID=9915236

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028105052A Expired - Fee Related CN100439394C (zh) 2001-05-24 2002-05-21 分泌性细菌效应蛋白的药物用途

Country Status (8)

Country Link
US (1) US20040208889A1 (enExample)
EP (1) EP1390400A2 (enExample)
JP (2) JP2004533250A (enExample)
CN (1) CN100439394C (enExample)
AU (1) AU2002256803B2 (enExample)
CA (1) CA2448963A1 (enExample)
GB (1) GB0112687D0 (enExample)
WO (1) WO2002096467A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
US20060068469A1 (en) * 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
AU2006233929B2 (en) * 2005-04-11 2012-05-31 Yeda Research And Development Co.Ltd. Chimeric proteins comprising Yersinia Yop, their preparation and pharmaceutical compositions containing them
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
EP2550366B1 (en) * 2010-03-23 2014-11-12 IMBA-Institut für Molekulare Biotechnologie GmbH Methods for identifying inhibitors of the type iii secretion system
US20130273092A1 (en) * 2010-10-22 2013-10-17 Trudeau Institute Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
WO2012163289A1 (zh) 2011-06-01 2012-12-06 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
US10633643B2 (en) * 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054033A1 (en) 2018-01-25 2021-02-25 The Wistar Institute Of Anatomy And Biology Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Conjugate Composed of Nerve Gowth Factor Coulped to aNon-toxic Derivative of Clostridium botulinum NeurtotoxinType A can Inhibit Neurotransumitter Reledase In Vitro. JOHN A. ET AL.Growth Factors,Vol.18 . 2000
A Conjugate Composed of Nerve Gowth Factor Coulped to aNon-toxic Derivative of Clostridium botulinum NeurtotoxinType A can Inhibit Neurotransumitter Reledase In Vitro. JOHN A. ET AL.Growth Factors,Vol.18 . 2000 *
Shiga 素养导向药物的初步研究. 梁龙等.卫生研究，第27卷. 1998
Shiga 素养导向药物的初步研究. 梁龙等.卫生研究，第27卷. 1998 *

Also Published As

Publication number Publication date
WO2002096467A2 (en) 2002-12-05
JP2004533250A (ja) 2004-11-04
JP2009286794A (ja) 2009-12-10
CA2448963A1 (en) 2002-12-05
GB0112687D0 (en) 2001-07-18
WO2002096467A3 (en) 2003-04-10
AU2002256803B2 (en) 2006-11-09
US20040208889A1 (en) 2004-10-21
CN1531549A (zh) 2004-09-22
EP1390400A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
CN100439394C (zh) 分泌性细菌效应蛋白的药物用途
Vasconcelos et al. Therapeutic potential of cell-penetrating peptides
US7727538B2 (en) Methods and compounds for the treatment of mucus hypersecretion
CN103987728B (zh) 抗癌融合蛋白
AU2002256803A1 (en) Pharmaceutical use for secreted bacterial effector proteins
US20120128700A1 (en) Constructs for delivery of therapeutic agents to neuronal cells
CN101432296A (zh) 聚乙二醇化的突变的肉毒梭菌毒素
JP2002523377A (ja) 粘液過剰分泌の治療のための組換えボツリヌス菌毒素
WO2018109447A1 (en) Neurotoxins
AU1059400A (en) Delivery of superoxide dismutase to neuronal cells
EP1523336B1 (en) Targeted agents for nerve regeneration
US7368532B2 (en) Constructs for delivery of therapeutic agents to neuronal cells
JP6910961B2 (ja) 選択細胞への分子送達に適用する遺伝子操作したボツリヌス菌毒素
Saffarian et al. TAT-BoNT/A (1–448), a novel fusion protein as a therapeutic agent: analysis of transcutaneous delivery and enzyme activity
Lorenzetti et al. Genetic grafting of membrane‐acting peptides to the cytotoxin dianthin augments its ability to de‐stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin‐toxin conjugates
Lin et al. Purification and characterization of a novel cell-penetrating carrier similar to cholera toxin chimeric protein
WO2022241167A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
Liu et al. Design, preparation and characterization of octopus-like self-releasing intracellular protein transporter LEB5 based on Escherichia coli heat-labile enterotoxin
US20220160874A1 (en) Neurotrophic factor protein conjugates and related embodiments
WO2022240407A1 (en) Delivery constructs derived from bacterial toxins and uses thereof
Méré et al. Increasing stability and toxicity of Pseudomonas exotoxin by attaching an antiproteasic Peptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081203

Termination date: 20100521